Navigation Links
Colony in Biological Technology

UC Riverside researcher develops novel method to grow human embryonic stem cells

... called Rho-Rock, which the hESCs use during colony formation and which plays an important role in ... pathway, they found, as expected, that the normal colony formation of hESCs was considerably impaired. ... now, it was generally assumed that the hESC colony formation was pivotal for maintaining ...

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

... disease after inhalation. The BNP(TM) technology provided similar colony counts for anthrax in 6 hours as obtained with the traditional Petri method in 24 hours. For Bubonic plague, the BNP(TM) colony count in 24 hours was also similar to what the traditional methodology ...

New designer toxins kill Bt-resistant insect pests

... then teamed up with Tabashnik to test their modified toxins on UA's colony of Bt-resistant pink bollworms, major cotton pests. Team member ... Tim Dennehy and Yves Carrire knew the Bt-resistant pink bollworms in their colony had a mutant version of cadherin. Tabashnik said, "These resistant ...

Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology

... Indian approvals for Oncology Biopharmaceuticals i.e. GCSF (Granulocyte colony Stimulating Factor), GM-CSF (Granulocyte Macrophage colony Stimulating Factor) and IL-2 (Interleukin-2). For the latter two, Zenotech ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Announces Pricing of Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Announces Public Offering of Common Stock

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Added to Russell 3000 Index

... in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Scientists discover 'dancing' algae

... matrix about half a millimetre in diameter. Each of the surface cells has two hair-like appendages known as flagella, whose beating propels the colony through the fluid and simultaneously makes them spin about an axis. The researchers found that colonies swimming near a surface can form two types ...

Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada

... (psyllium husk). Presented in an enteric-coated, gluten-free, vegetarian gel capsule, each serving of Kibow Biotics contains a total of 30 billion colony forming units (CFU). When taken orally after every meal (3 times) on a daily basis, Kibow Biotics has the potential to help maintain healthy ...

Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May

... focuses on automating the pre-analytical and analytical steps involved with traditional microbial enumeration with a product line that includes colony counters, plating systems, anaerobic workstations, susceptibility test software, air samplers and sample prep tools. For more information, contact ...

Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the Cowen Health Care Conference on March 17, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Buckyballs could keep water systems flowing

... membranes showed less bacterial attachment than non-treated membranes. After three days, the membranes treated with buckyballs had on average 20 colony forming units, the method by which bacterial colonies are counted. "In contrast, the number of bacterial colonies on the untreated membrane was ...

Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses

... from biomass. Tuesday, February 17, 2009 6:30 - 9:30 p.m. The Enterprise Center at Foley Hoag, The Bay colony Corporate Center 1000 Winter St., Ste. 4000 Waltham, MA Cost: $25. public $10. students & active military For ...

Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG

... MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present at the RBC Capital Markets Healthcare Conference

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology

... which outlined the methods and techniques used to change one bacterial species, Mycoplasma capricolum, into another, Mycoplasma mycoides Large colony (LC), by replacing one organism's genome with the other one's genome. Genome transplantation was the first essential enabling step in the field of ...

Micromet Added to NASDAQ Biotechnology Index

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

InterMune Reports Third Quarter 2008 Financial Results and Business Highlights

... of ITMN-191 with the active moiety of polymerase inhibitor R7128 (Roche/Pharmasset) in a 14-day replicon clearance assay and in a 3-week colony formation assay resulted in clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral variants. These ...

Micromet, Inc. Reports Third Quarter 2008 Financial Results

... MT 203 being developed in collaboration with Nycomed. MT 203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL

... Zenyth Therapeutics Limited (now part of CSL Limited) and is developing therapeutic antibodies that inhibit the activity of the cytokine granulocyte colony stimulating factor (G-CSF). The collaboration built on the discovery by Professor Ian Wicks, a clinical rheumatologist at the Walter and Eliza Hall ...

MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology

... is a MAb with potential to help patients with rheumatoid arthritis. The antibody targets the alpha sub-unit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). CAM-3001 is a phase 1 clinical stage program. -- ICOS - ICOS (Inducible costimulator) is a receptor on ...

Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008

... Biologics Program -- Completed clinical trial demonstrating the bioequivalence of INS-19, the company's recombinant human granulocyte colony stimulating factor (G-CSF), to Neupogen(R), an FDA-approved G-CSF product for the treatment of neutropenia that recorded 2007 sales of ...

Insmed Announces First Quarter 2008 Financial Results

... and Healthcare products Regulatory Agency to initiate a clinical trial for Insmed's most advanced FOB candidate, INS-19 (Granulocyte colony Stimulating Factor or G-CSF), a FOB of the FDA-approved product Neupogen(R), which had U.S. sales of approximately $0.9 billion in ...
Other Contents
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
(Date:7/11/2014)... According to new report "C4ISR Market (2014 - ... a CAGR of 2.28% to reach $93.04 billion ... and 76 figures spread through 185 pages and ... , Early buyers will receive 10% customization on ... provides market analysis of the global C4ISR Market ...
(Date:7/11/2014)... the number of deer in an area can lower ... infections among people, new research indicates. "Our study ... human interactions with deer, infected nymphal ticks and human ... White-tailed deer are the primary host for adult blacklegged ... study included nearly all the permanent residents of a ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and ... is expected to pose the biggest challenge to suppliers ... growth to the ongoing spread of AIDS – still ... major factor leading to the upsurge of opportunistic infections, ... broader availability of immunosuppressants, among others. , Market ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Children ... greater risk for complications and potentially even death ... a new study. However, the Johns Hopkins ... "miniscule." The researchers analyzed data on nearly ... United States underwent over a 22-year period. ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2
Other TagsOther Tags